Publication: The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity
Loading...
Date
2016
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
American Society for Microbiology
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Tubman, Venée N., Pedro Mejia, Boris E. Shmukler, Amy K. Bei, Seth L. Alper, James R. Mitchell, Carlo Brugnara, and Manoj T. Duraisingh. 2015. “The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity.” Antimicrobial Agents and Chemotherapy 60 (1): 613–16. https://doi.org/10.1128/aac.01668-15.
Abstract
Senicapoc, a Gardos channel inhibitor, prevented erythrocyte dehydration in clinical trials of patients with sickle cell disease. We tested the hypothesis that senicapoc-induced blockade of the Gardos channel inhibits Plasmodium growth. Senicapoc inhibited in vitro growth of human and primate plasmodia during the clinical blood stage. Senicapoc treatment suppressed P. yoelii parasitemia in vivo in C57BL/6 mice. The reassuring safety and biochemical profile of senicapoc encourage its use in antimalarial development.
Description
Other Available Sources
Research Data
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service